One example includes ivonescimab, a bispecific antibody against PD-1 and VEGF, which demonstrated significantly improved PFS when compared with pembrolizumab in treatment naïve stage IV NSCLC in those with a PD-L1 TPS ≥ 1% [64]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.